Related Experiment Video
Updated: Sep 23, 2025
Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
Published on: August 17, 2022
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
1Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd., 1289 Yishan Road, Shanghai 200233, China; Fosun Pharma USA Inc, 91 Hartwell Avenue, Suite 305, Lexington, MA 02421, USA.
Abstract:
mRNA vaccines have gained popularity over the last decade as a versatile tool for developing novel therapeutics. The recent success of coronavirus disease (COVID-19) mRNA vaccine has unlocked the potential of mRNA technology as a powerful therapeutic platform. In this review, we apprise the literature on the various types of cancer vaccines, the novel platforms available for delivery of the vaccines, the recent progress in the RNA-based therapies and the evolving role of mRNA vaccines for various cancer indications, along with a future strategy to treat the patients. Literature reveals that despite multifaceted challenges in the development of mRNA vaccines, the promising and durable efficacy of the RNA in pre-clinical and clinical studies deserves consideration. The introduction of mRNA-transfected DC vaccine is an approach that has gained interest for cancer vaccine development due to its ability to circumvent the necessity of DC isolation, ex vivo cultivation and re-infusion. The selection of appropriate antigen of interest remains one of the major challenges for cancer vaccine development. The rapid development and large-scale production of mRNA platform has enabled for the development of both personalized vaccines (mRNA 4157, mRNA 4650 and RO7198457) and tetravalent vaccines (BNT111 and mRNA-5671). In addition, mRNA vaccines combined with checkpoint modulators and other novel medications that reverse immunosuppression show promise, however further research is needed to discover which combinations are most successful and the best dosing schedule for each component. Each delivery route (intradermal, subcutaneous, intra tumoral, intranodal, intranasal, intravenous) has its own set of challenges to overcome, and these challenges will decide the best delivery method. In other words, while developing a vaccine design, the underlying motivation should be a reasonable combination of delivery route and format. Exploring various administration routes and delivery route systems has boosted the development of mRNA vaccines.
Insights
Messenger RNA (mRNA) vaccines offer a powerful platform for cancer therapy, demonstrating promising efficacy despite development challenges. Future strategies involve optimizing delivery routes and antigen selection for personalized and combination cancer vaccines.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Messenger RNA (mRNA) vaccines have emerged as a significant therapeutic tool, with recent successes in coronavirus disease (COVID-19) highlighting their potential.
- The versatility of mRNA technology has positioned it as a powerful platform for developing novel therapeutics, particularly in oncology.
Purpose of the Study:
- To review the literature on various cancer vaccine types, novel delivery platforms, and recent advancements in RNA-based therapies.
- To explore the evolving role of mRNA vaccines in treating diverse cancer indications and outline future treatment strategies.
Main Methods:
- Literature review of pre-clinical and clinical studies on mRNA vaccine efficacy and delivery.
- Analysis of novel platforms, including mRNA-transfected dendritic cell (DC) vaccines and personalized/tetravalent mRNA vaccines.
- Examination of combination therapies involving mRNA vaccines with checkpoint modulators and other immunomodulatory agents.
- Assessment of various delivery routes (e.g., intradermal, subcutaneous, intravenous) and their associated challenges.
Main Results:
- mRNA vaccines show promising and durable efficacy in pre-clinical and clinical studies, despite facing development challenges.
- mRNA-transfected DC vaccines offer an alternative by bypassing the need for ex vivo DC manipulation.
- Rapid development and large-scale production enable personalized (e.g., mRNA 4157) and tetravalent (e.g., BNT111) mRNA vaccines.
- Combination therapies with checkpoint modulators show potential but require further research for optimal combinations and dosing schedules.
- Delivery route selection is critical, with each route presenting unique challenges that influence vaccine design.
Conclusions:
- mRNA technology represents a significant advancement in cancer vaccine development, offering a versatile and rapidly producible platform.
- Overcoming challenges in antigen selection and optimizing delivery routes are crucial for maximizing the efficacy of mRNA cancer vaccines.
- Future strategies should focus on personalized vaccines, combination therapies, and tailored delivery systems to advance mRNA-based cancer treatment.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...